HSP60 IS THE MOST PREDICTIVE HEAT SHOCK PROTEIN DURING LARGE BOWEL CARCINOGENESIS by Rappa, F.
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
DIPARTIMENTO DI BIOMEDICINA SPERIMENTALE E NEUROSCIENZE CLINICHE 
Dottorato di ricerca in Medicina Sperimentale e Molecolare 
(Molecular and Experimental Medicine) 
HSP60 IS THE MOST PREDICTIVE HEAT SHOCK PROTEIN DURING 
LARGE BOWEL CARCINOGENESIS 
 
 TESI DI  
 DR. FRANCESCA RAPPA 
TUTOR  
CHIAR.MA PROF.SSA FELICIA FARINA 
 
 
 
CO-TUTOR 
DR. NUNZIA SCIBETTA 
XXIV CICLO  
SSD BIO/16 Anatomia Umana 
 COORDINATORE DEL DOTTORATO 
 CHIAR.MO PROF. GIOVANNI ZUMMO 
2 
 
ACKNOWLEDGMENTS 
 
I wish to thank: 
Department of Experimental Medicine and Clinical Neuroscience, University 
of Palermo, Palermo, Italy. 
Prof. Giovanni Zummo 
Prof. ssa Felicia Farina 
Prof. Francesco Cappello 
Prof. Fabio Bucchieri  
Dr. Rosario Barone 
Dr. Claudia Campanella 
Dr. Celeste Caruso Bavisotto 
Dr. Sabrina David 
Dr. Antonella Marino Gammazza 
Dr. Claudia Sangiorgi 
DICHIRONS Department of the University of Palermo, Italy. 
            Prof. Carmelo Sciumè 
Surgical Anatomy Unit of the Civico Hospital, Palermo, Italy. 
 Dr. Nunzia Scibetta 
 
 
 
 
 
 
 
3 
 
 
INDEX 3 
Introduction 5 
1. The anatomy of large bowel 6 
1.1. General Features 6 
1.2. Microscopic Features 8 
1.3. Macroscopic Aspects of the Individual Intestinal Tracts   11 
2. Large Bowel Carcinoma 15 
      2.1. Epidemiology and Etiology 15 
      2.2. Epithelial Polyps and Carcinogenesis 16 
      2.3. Morphological Aspects of Large Bowel Carcinoma 18 
3. Heat Shock Protein 20 
4. Chaperonopathies 23 
5. Exosomes: A Way For Intercellular Comunication 24 
Aim 28 
Experimental Procedures 29 
1. Specimen collection 30 
2. Histological analysis 31 
3. Immunohistochemistry 32 
4. Western Blotting 33 
5. Total RNA extraction 34 
6. RT-PCR 35 
7. ELISA Assay for Human Hsp60 36 
8. Transmission electron microscopy (TEM) 37 
      8.1. LR-White inclusion 37 
      8.2. Immunogold 37 
9. Exosome isolation from plasma 38 
      9.1. Exosomes assessment procedure 38 
      9.2. Western Blotting analysis for Hsp60 in Exosomes 39 
10. Double immunofluorescence on adenocarcinoma tissue 40 
11. Statistical Analyses 41 
Results 42 
1. Histological analysis 43 
4 
 
2. Immunohistochemical analysis 44 
3. Western Blotting analysis 47 
4. RT-PCR 48 
5. ELISA Assay for Human Hsp60 49 
6. Immunogold experiments by TEM 50 
7. Exosomes assessment procedure 51 
8. Western Blotting analisys for Hsp60 in Exosomes 53 
9. Double immunofluorescence analysis 54 
Discussion 56 
References 61 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
 
 
 
 
 
 
 
 
 
 INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
6 
 
1. ANATOMY OF THE LARGE INTESTINE 
1.1 GENERAL FEATURES 
The large intestine extends from the ileocaecal valve to the anus and is approximately 
1.5 m long in adults, although there is considerable variation in its length. In the 
abdominal cavity it forms a border around the loops of small intestine that are located 
centrally within the abdomen. The large intestine begins in the right iliac fossa as the 
caecum which becomes the ascending colon that passes upwards in the right lumbar 
region and hypochondrium to the inferior face of the liver where it bends to the left 
constituting the hepatic flexure (right colic flexure) and becomes the transverse colon. 
This part of intestine across the abdomen until it reaches the left hypochondrium, where 
it curves inferiorly to form the splenic flexure (left colic flexure) and becomes the 
descending colon that proceeds through the left lumbar and iliac regions to constitute 
the sigmoid colon in the left iliac fossa. The sigmoid colon descends deep into the 
pelvis and becomes the rectum which ends in the anal canal at the level of the pelvic 
floor (Fig 1). The wall of the large intestine is relatively thinner than the small intestine. 
Along its entire length, on the outer surface, the large intestine shows sacculations 
(haustrations), which may partly be due to the presence of the taeniae coli that are three 
longitudinal bands of longitudinal muscle layer (1). 
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Fig 1 Schematic vision of large bowel. 
http://apbrwww5.apsu.edu/thompsonj/Anatomy%20&%20Physiology/2020/2020%20Exam%20Reviews/Exam%203/colon%20diag
ram.jpg 
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1.2 MICROSCOPIC FEATURES 
In analogy to other portions of the alimentary canal, the intestinal wall is constituted by 
four tunics that are distinguished from the inside outwards in tunica mucosa, tunica 
submucosa, muscularis and tunica serosa or adventitia at the points where it is not 
covered by the peritoneum (Fig. 2). The mucosa is pale, smooth, and, in the colon, 
raised into numerous crescent-shaped folds between the sacculi (in the rectum it is 
thicker, darker, more vascular). It is constituted from a lining epithelium, from the 
underlying lamina propria and muscularis mucosae. 
The normal homeostasis of the colonic mucosa requires a balance between proliferative 
processes at the base of the crypt glandular (crypt is the lower portion of the gland) and 
apoptotic processes in the most superficial part of the gland. The apoptosis is a 
fundamental process for the physiological turnover of senescent cells. Several studies 
have shown that a reduction of the apoptotic processes can increase the risk of cancer of 
the colon and rectum (2). 
The cell types that constitute the glandular epithelium of the colon are (1): 
1. Columnar (absorptive) cells: are the most numerous of the epithelial cell types. 
They are responsible for ion exchange, water resorption and other transepithelial 
transport. They all bear apical microvilli, which are shorter and less regular than 
those on enterocytes of the small intestine. These cells have typical junctional 
complexes around their apices, which limit extracellular diffusion from the 
lumen across the intestine wall. 
2. The goblet cells: maintain secretory granules in the apical portion of the 
cytoplasm, the secretion of these cells is predominantly composed of mucin, it is 
also rich in antibodies of the IgA type. 
3. Microfold (M) cells: as in the small intestine, are cells with long microvilli 
located in the epithelium overlying the lymphoid follicles. Their function is 
related to the transport and presentation of antigens.  
4. Stem cells: they give rise to all the above mentioned types of epithelial cells, are 
found in the bottom of the intestinal glands and periodically undergo mitotic 
divisions. These cells are long-lived, able to self-renew and to differentiate into 
different cell types. Their mechanisms of proliferation and differentiation are 
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regulated by the so-called "niche" stem cell which consists of a complex stromal 
microenvironment that surrounds the stem cells themselves, and is constituted 
by the extracellular matrix and by different cell types, (neural cells, 
lymphocytes, macrophages, endothelial cells, fibroblasts and myofibroblasts). 
Each of these cell types regulates the activity of stem cells through the 
production of growth factors and cytokines. 
5. Neuroendocrine cells: sit at the base of the glands and release their secretions 
in the vessels of the lamina propria. 
 
The lamina propria of the tunica mucosa is composed of fibrillar and reticular 
connective tissue that provides support to the epithelium. In its interior it has capillaries 
lymphocytes, plasma cells, eosinophils and macrophages. 
The muscularis mucosa is composed of two thin layers of smooth muscle, one circular 
and one longitudinal. It separates the tunica mucosa from the submucosa. 
The submucosa consists of dense connective tissue containing several cell types such 
as lymphocytes, plasma cells, macrophages, blood vessels and lymphatics. Along its 
inner edge, the submucosa contains a network of nerve fibers that form the submucosal 
plexus of Meissner which contains sensory neurons, parasympathetic ganglia and 
postganglionic sympathetic fibers. The submucosa is raised to form the axis of the 
circular folds together with the mucous membrane and allows the implementation of the 
considerable variations in size, in the transverse and longitudinal directions, which 
accompany the peristaltic movements of the gut tube, giving at the same time an 
adequate support, elasticity and resistance. 
The muscle layer is constituted by two layers of smooth muscle: an external 
longitudinal and internal circular one. The longitudinal bundles do not form a 
continuous layer, but thicken to form longitudinal strips, known as taeniae coli. 
 
 
Between the two layers of smooth muscle is located the myenteric plexus or Auerbach's 
plexus, consisting of parasympathetic ganglia and post-ganglionic fibers synapse, which 
is fundamental for the coordination of the movements of the intestine. In the rectum the 
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taeniae disappear. The circular muscle bundles form a thin layer in the cecum and 
colon, and rectum form a thick layer in the anal canal and give rise to the internal anal 
sphincter consists of smooth muscle involuntary; the external anal sphincter is 
constituted by a ring of striated muscle that contracts and relaxes under the control of 
the will. 
The tunica serosa consists of visceral peritoneum in intraperitoneal tracts while consists 
of adventitia on retroperitoneal tracts of intestine. Along the colon the peritoneum forms 
small fat-filled appendices epiploicae which are most numerous on the sigmoid and 
transverse colon but generally absent from the rectum. A connective tissue attaches the 
peritoneum to the muscularis externa. The adventitia is dense reticular connective. 
 
 
Fig 2 Schematic vision of the wall of large bowel. http://media-2.web.britannica.com/eb-media/19/74319-
004-68DBB5D6.jpg 
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1.3 MACROSCOPIC ASPECTS OF THE INDIVIDUAL 
INTESTINAL TRACTS 
Cecum 
The cecum is the first portion of the large intestine, long on average 6 cm wide and 
about 7.5 cm, it has the shape of a bag to the bottom end, and is placed in the right iliac 
fossa, in continuity, at the proximal with the terminal ileum and distal to the ascending 
colon. From the posteromedial surface of the cecum, approximately 2-3 cm orifice 
ileocecal originates vermiform appendix, a tubular diverticulum of variable length from 
2 to 15cm. 
The cecum is located in the lodge cecal and is bordered posteriorly by the fascia of the 
psoas muscle that is covered by the lumbo-iliac fascia and the parietal peritoneum, by 
the right ureter, the external iliac vessels, the gonadal vessels and nerves genito and 
femoral-cutaneous covered by parietal peritoneum; postero-laterally by the fascia of the 
iliacus muscle, medially by the latest loops of small bowel; anteriorly by the anterior 
abdominal wall. The cecum is usually entirely covered by peritoneum but sometimes in 
its postero-superior portion cannot be covered by peritoneum and lie directly on the 
connective fascia iliaca (1). 
The cecum is vascularized by the anterior and posterior caecal branch of ileocolic artery 
that arises from the right side of the superior mesenteric artery. Venous blood from the 
wall of the caecum drains into mesenteric arcades and subsequently into segmental 
veins that converge into the superior mesenteric vein a branch of portal vein.  
Colon 
The colon is the middle part of the large intestine, is on average 1.30 meters long and is 
divided into the ascending colon, transverse colon, descending colon and sigmoid colon. 
Its diameter ranges from about 5 cm in ascending colon to about 3 cm in sigmoid colon. 
The ascending colon is about 15 cm long, starts at the upper edge of the cecum to 
ascend along the right side of the rear wall of the abdominal cavity until the lower 
surface of the right lobe of the liver on which leaves an imprint and, then turns abruptly 
forwards and to the left, at the hepatic flexure (2,3). It is a retroperitoneal structure 
covered anteriorly and on both sides by peritoneum. Its posterior surface is separated by 
loose connective tissue from the iliac fascia, the iliolumbar ligament, quadratus 
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lumborum, the aponeurosis of transversus abdominis, and the anterior peri-renal fascia 
inferolateral to the right kidney. Anteriorly it is in contact with loops of ileum, the 
omentum and, partly, the anterior abdominal wall. The transverse colon is 
approximately 50 cm long, and extends from the hepatic flexure in the right lumbar 
region across into the left hypochondriac region, where it curves posteroinferiorly as the 
splenic flexure. Its location and its length are highly variable. The transverse colon is 
intraperitoneal and is suspended from the anterior border of the body of the pancreas by 
the transverse mesocolon which is attached from the inferior part of the right kidney, 
across the second part of the duodenum and pancreas, to the inferior pole of the left 
kidney. The transverse colon superiorly adjoins with the liver and gallbladder, with the 
greater curvature of the stomach and with the rear end of the spleen; inferiorly adjoins 
with the small intestine, anteriorly with the greater omentum and posteriorly with the 
descending part of the duodenum-jejunum and some loops of the jejunum and ileum. 
The descending colon is approximately 25 cm long. It descends through the left 
hypochondrium and lumbar region following the lateral border of the lower pole of the 
left kidney, then descending in the angle between psoas major and quadratus lumborum 
to the iliac crest and, curves inferomedially to become the sigmoid colon. The 
descending colon is smaller in caliber, and is retroperitoneal though sometimes is 
covered posteriorly by peritoneum.  
The sigmoid colon begins below the pelvic inlet and ends at the rectum. 
Characteristically it forms a mobile loop which normally lies in the lesser pelvis, but its 
length (about 40 cm) and form are the most variable of the total colon. It is usually 
completely invested in peritoneum. The sigmoid colon initially descends over the iliac 
crest into the pelvis and remains in contact with the peritoneum overlying iliacus 
muscle, and finally curve backward and reaches the median plane at the level of the 
third sacral vertebra and then fold down to terminate in the rectum.  However its 
position is extremely variable. 
The arterial vascularization of the colon is quite variable but all involved arteries are 
branches arising by superior and inferior mesenteric arteries. In particular the ascending 
colon and the first portion of transverse colon are vascularized by the right colon artery 
which anastomoses with the ileo-colic artery and the middle colic artery, a branch of 
superior mesenteric artery; the proximal two thirds of the transverse colon are 
vascularized by middle colic artery, while the distal third by colic artery of the left, a 
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branch of inferior mesenteric artery; the descending colon is perfused by the left colic 
branch of the inferior mesenteric artery which anastomoses with the sigmoid arteries; 
the sigmoid colon is perfused by the sigmoid arteries that anastomose with the superior 
rectal artery, the last branch of the inferior mesenteric artery (1) (Fig.3). 
Rectum 
The rectum is 15 cm long, follows the sigmoid colon from the level of the third sacral 
vertebra and ends at the upper end of the anal canal. The rectum is divided in pelvic 
tract and perineal tract. The pelvic tract, in its descent from the third sacral vertebra, 
follows the concavity of the sacrum and coccyx; its upper part has the same diameter of 
the sigmoid colon, while its lower part is dilated to form the rectal ampulla. The rectum 
crosses the pelvic floor muscle membrane of the perineum. The rectum pelvic, in its 
upper portion is covered by the peritoneum on the anterior and lateral faces, while in its 
middle portion is covered by peritoneum only on the front face (1). The rectum differs 
from the sigmoid colon in having no sacculations or appendices epiploicae. The taeniae 
blend approximately 5 cm above the rectosigmoid junction, forming two wide muscular 
bands which descend anteriorly and posteriorly in the rectal wall. The rectum anteriorly 
is related with the loops of the sigmoid colon and sometimes with the loops of the 
ileum, as well as the base of the bladder (in males) or the neck and body of the uterus 
(in females); inferiorly it is related with the bladder and, in males, with seminal vesicles, 
deferens duct, terminal tract of ureters and prostatic gland, while, in females, the rectum 
is related with the inferior tract of the vagina canal (1). 
The upper two-thirds of the rectum are vascularized by superior rectal artery, branch 
terminal of inferior mesenteric artery; the middle third is supplied by the middle rectal 
arteries, branches of the internal iliac artery, or from the inferior vesical artery (vaginal 
artery in females); the distal third is vascularized by ascending branches of the inferior 
rectal arteries, terminal branches of the internal pudendal arteries. The veins are 
arranged in a network anastomotic, the hemorrhoidal venous plexus, which superiorly is 
tributary of the portal venous system through the hemorrhoidal branch of the inferior 
mesenteric vein, while inferiorly is a tributary of the internal iliac vein through the 
middle and inferior hemorrhoidal veins. In particular, the veins form the venous plexus 
which are distinguished in the internal hemorrhoid plexus or submucosal plexus and 
external hemorrhoidal plexus outside the muscularis tunic. Therefore, at rectal level, 
there is an anastomosis between the portal venous system and the systemic venous 
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system (Fig.3). The rectum is continuous with the anal canal at a point where its muscle 
layer merges with the voluntary muscle (striated) of the pelvic floor, giving rise to the 
anal sphincter. 
 
Fig 3: Vascularization of large bowel. 
http://www.as.miami.edu/chemistry/2086/chap%2024/Chapter%2024-newPART2_files/image017.jpg 
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2. LARGE BOWEL CARCINOMA 
2.1 EPIDEMIOLOGY AND ETIOLOGY 
Colorectal cancer is a malignancy of great relevance social and health care. This 
neoplasia is common in Northwest Europe, North America, and other Anglo-Saxon 
areas. Its incidence is instead low in Africa, Asia, and some regions of South America 
(5). Globally, Colorectal cancer is the third most commonly diagnosed cancer in males 
and the second in females, with over 1.2 million new cases and 608,700 deaths 
estimated each year. In the United States, it is 12% of malignant tumors with 150000 
new cases each year and, approximately 50,830 deaths. In Italy, the carcinoma of the 
colon and rectum is the second cause of death from malignancy in males (after lung 
cancer) and in women (after breast cancer), with approximately 35,000 new cases a year 
with 16,000 deaths. It is more frequent in males (52.2/100000) than in females (37.5 / 
100,000). The mean age of incidence is 62 years. Only 1 to 2% of cases occur before 
age 40. The causes and pathogenesis of colorectal carcinoma are related to both 
environmental and genetic factors (6) Diet is implicated in the process of carcinogenesis 
of colorectal cancer. The reduced consumption of vegetables, and fibers and the 
increased consumption of fats and animal proteins are risk factors for the disease. The 
dietary factors are related to their influence on the intestinal microflora and on the 
chemical composition of the nutrients (7-9). Among the environmental factors will also 
recognize occupational factors (10). The genetic factors are related to the presence of 
familial syndrome such as Familial Polyposis, Gardner Syndrome, and Lynch 
Syndrome. Moreover, the presence of two or more first-degree relatives with colorectal 
cancer, in a family increases threefold the risk of development of this tumor (11). 
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2.2 EPITHELIAL POLYPS AND CARCINOGENESIS 
Most tumors of the colon-rectum are derived from malignant transformation of polyps. 
This lesion is a clinical terms of any circumscribed tumor or growth that project above 
the surrounding mucosa. Polyps may be hamatomatous, hyperplastic, or adenomatous in 
nature. The hamatomatous polyps have no malignant potential. The hyperplastc polyps 
are benign epithelial proliferations and, are not considered to be premalignant. The 
adenomatous polyps, instead, are premalignant lesions. Adenomas are very common in 
the large intestine and are of clinical importance because they may develop into cancer. 
The incidence of adenomas parallels the incidence of large bowel carcinoma. Grossly, 
adenomas may be sessile or pedunculated and single or multiple. Microscopically the 
epithelium is adenomatous with an increase in the number of glands and cells compared 
to the normal mucosa. By definition, adenomas consist of dysplastic epithelium. The 
cells are enlarged, elongated, with hyper-chromatic nuclei that are stratified within the 
cell. Mucus production is significantly reduced or absent. Mitotic figures are prominent. 
Adenomas are traditionally divided into three types: tubular, tubule-villous, and villous 
according to the growth pattern. Tubular adenomas show gland and tubular structures 
that are separated from each other by normal lamina propria. In the villous adenomas 
there are leaf-like projections lined by dysplastic glandular epithelium comprise more 
than 80% of the luminal surface. These villi are covered by adenomatous epithelium. 
The tubulovillous adenomas show histological aspects of both tubular and villous 
adenomas. The dysplasia of adenomas may be mild, moderate and severe according to 
the architectural and cytological aspects.  
The carcinogenetic model (proposed by Volgestein and his colleagues in the 1988) (12) 
of large bowel is an example of multistep process in which the transformation of normal 
large bowel mucosa in invasive tumor involves the accumulation of different genetic 
alterations. In fact the process of malignant transformation of epithelial tissue has been 
made possible by the demonstration that the morphologic progression from normal 
epithelium to hyper-proliferative lesions, and then to adenomatous lesions, and finally 
to carcinoma, is accompanied and caused by a series of molecular alterations (Fig.4). 
These molecular alterations include genetic mutations that active oncogenes and, 
instead, inactive tumor-suppressor genes. The most important of these genes are APC, 
mismatch repair genes, p53, K-ras, and DCC (13,14). 
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Fig.4 Schematic representation of morphologic and molecular events in colorectal tumorigenesis. The 
loss of APC gene (located on chromosome 5) would be responsible for an increased cell proliferation 
(hyper-proliferative epithelium) and subsequent mutation of ras oncogene (located on chromosome 12), 
involved in the regulation of cell growth, would be responsible for the formation of a dysplastic polyp 
(adenoma); the loss of DCC gene (Deleted in Colon Cancer, located on chromosome 18) and the mutation 
of p53 gene (located on chromosome 17) confer to the cells a selective advantage of growth and invasive 
and metastatic ability. 
http://4.bp.blogspot.com/RqRsi5m3E_s/UQJks7jG_BI/AAAAAAAAAm8/JDN3cyESfIc/s400/F1.large.jpg 
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 2.3 MORPHOLOGICAL ASPECTS OF LARGE BOWEL 
CARCINOMA 
Approximately 50% of all carcinomas occur in the recto sigmoid area, 30% occur in the 
cecum and ascending colon tract and 10% in the transverse colon. There is evidence of 
changing distribution in recent years, with an increasing proportion of more proximal 
carcinomas (15). 
The macroscopic features are influenced by the phase in the natural history of tumors at 
the time of discovery. Grossly, most colorectal cancer are either polypoid or exophytic 
with predominantly intraluminal growth, ulcerative/infiltrating with predominantly 
intramural growth, diffusely infiltrative/linitis plastica with subtle endophytic growth, 
and annular with circumferential involvement of the colorectal wall and constriction of 
the lumen. Generally, polipoid cancers have a better prognosis than ulcerative cancers. 
Overlap among these types is common (16) 
The World Health Organization classifies colorectal cancers in adenocarcinoma, 
mucinous adenocarcinoma, signet ring cell carcinoma, small-cell carcinoma, 
adenosquamous carcinoma, squamous cell carcinoma, medullary carcinoma, 
undifferentiated carcinoma (16). Adenocarcinoma is the most frequent histological type 
and, is gland-forming, with variability in the size and configuration of the glandular 
structures. This tumor can be gradated predominantly, on the basis of the extent of 
glandular appearances, and should be divided into well, moderately and poorly 
differentiated (Grading G). Poorly differentiated adenocarcinomas should show at least 
some gland formation or mucus production. The percentage of the tumour showing 
formation of gland-like structures can be used to define the grade. Well differentiated 
(G1) lesions exhibit glandular structures in > 95% of the tumour; moderately 
differentiated (G2) lesion has 50-95% glands; poorly differentiated (G3) 
adenocarcinoma has 5-50%; and undifferentiated (G4) carcinoma has < 5% (15) The 
tumor cells represent a combination of columnar and goblet cells. The carcinoma 
consistently elicits an inflammatory and desmoplastic reaction, which is particularly 
prominent at the border of tumor. Mucinous adenocarcinoma shows large lakes of 
extracellular mucin (> of 50% of the tumor mass). Signet-ring cells carcinoma is rare in 
large bowel and has a diffuse infiltration of cells with intracellular accumulation of 
mucin. Squamous carcinoma show squamous differentiation. The adenosquamous 
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carcinoma shows features of both squamous carcinoma and adenocarcinoma. Medullary 
carcinoma is characterized by sheets of malignant cells with abundant pink cytoplasm 
exhibiting prominent infiltration by intraepithelial lymphocytes. The undifferentiated 
carcinoma lack morphological evidence of differentiation and have variable histological 
features. In its growth, colorectal carcinoma extends through the muscularis propria into 
pericolic or perirectal soft tissue, involving contiguous structures. The two staging 
systems most commonly used by pathologists are the one proposed by the Dukes, 
modified by Asler and Coller, and TNM system. In both is considered the degree of 
invasion of intestinal wall, the degree of lymphatic node involvement and, the degree of 
metastasis. 
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3. HEAT SHOCK PROTEIN 
Molecular chaperones, many of which are Heat Shock Proteins (HSP), are an important 
class of molecules essential for cell life and survival. Hsps were first discovered as the 
products of genes induced by heat shock (17), but the term Hsp is used nowadays with 
great flexibility to indicate the products of genes that are induced by a number of 
chemical, physical and biological stressor (18). Both terms Hsp and chaperones are used 
often as synonyms but not all HSPs are chaperones and not all chaperones are Hsps. 
Hsps are part of the chaperoning system, a physiological system composed of Hsp-
chaperones, co-chaperones and co-factors of an organism (19). This physiological 
system is essential for the control of protein homeostasis and maintenance of correct 
and functional conformation of proteins in all fluids, cells, and tissues (19), and also, is 
important in some other processes not of necessity, related to protein homeostasis (20). 
Many Hsps have a chaperoning activity. As per the classic concept, the canonical 
function of Hsps is to assist nascent polypeptides in their correct folding and, when the 
protein is not properly folded or is defective, to assist protein refolding or degradation 
(21) (Fig5). 
 
Fig.5 Chaperoning functions of Hsps. From Macario  and  Conway  de  Macario, New  Eng. J.  Med.2005 
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Hsps have also other important “extra-chaperoning” functions such as participation in 
immune system regulation (20,23) cell differentiation (24), gene expression and DNA 
replication (25) programmed cell death (26,27), cellular senescence (20,28) and 
carcinogenesis ( 29,30). Chaperones usually do not work alone, but they form a team of 
molecules that works together. An example is the chaperonin complex of Hsp60 that is 
formed by identical subunits and co-works with Hsp10 and others small Hsps. Also 
Hsp70 form a team of co-worker molecules by interacting with Hsp40 and with a co-
factor NEF (31) Hsps (including Hsp60, Hsp10, Hsp70 and Hsp90) are constitutively 
expressed in cells, and for many years were considered typical intracellular. In fact they 
have an intracellular and pericellular localization being present in the mitochondria, in 
the cytosol, in cell membrane, in the nucleus, in the cell surface, and, also, have an 
extracellular localization being present in fluids such as blood, lymph and cerebrospinal 
fluids (19). Hsps may be released outside cells through microvesicles (such as 
exosomes) that are important for the intercellular cross-talk (32,33). Hsps are classified 
in various ways. These proteins were initially classified according to molecular weight 
expressed in KiloDaltond (kDa) (Table 1), but the expanding number of Hsps has made 
it necessary to revise the nomenclature (34). However the nomenclature based on 
molecular weight is the most used.                                        
Chaperone family Molecular weight (kDa) Main function(s) 
Heavy 100 or higher Prevents protein aggregation, helps protein 
folding.  
Hsp90 81-99 Protein folding, cytoprotection; intracellular 
signaling (e.g., steroid receptor); cell-cycle 
control. 
Hsp70 65-80 Prevents protein aggregation, protein folding, 
cytoprotection and anti-apoaptotic function.  
Hsp60 55-65 Prevention of protein aggregation, protein 
folding, cytoprotection, macrophage activator 
possibly through Toll-like receptor. 
CCT 55-63 Protein folding. 
Hsp40 35-54 Protein folding and refolding  together with 
Hsp70/Hsc70. 
Small Hsp 34 or less Anti-apoptotic function; cytoprotection. 
Hsp10 10 Protein folding together with Hsp60; modulation 
of immune system. 
Table 1 Classification of Hsps according to their molecular mass. From Rappa F et al. ANTICANCER 
RESEARCH 32: 5139-5150 (2012). 
  
 
Hsps are implicated in the pathogenesis of a range of tumors. In fact, these proteins are 
involved in various metabolic mechanisms of neoplastic cells, such as proliferation, 
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invasiveness, induction of neoangiogenesis and metastasization. Hsps are involved in 
vital mechanisms of malignant cells and their elevated levels can protect cancerous cells 
against apoptosis. Regard to the mechanisms of apoptosis, many Hsps participates in 
both intrinsic and extrinsic pathways interfering with molecules essential in the 
apoptotic process. Hsp27 and Hsp70 interfere with apoptosis through inhibition of 
aptosome formation in intrinsic pathway (35,36), while Hsp90 has a role in modulating 
the function of TNF receptor-1, a molecular receptor involved in the extrinsic pathway 
of apoptosis (37).Moreover, Hsp60 favors the cell proliferation through its ability to 
survive to apoptotic stimuli (38); Hsp90 is associated with many of the key signaling 
molecules that mediate autonomous growth in cancer (39); Hsp27 and Hsp70 mediate 
endothelial cell mobility and favors tumor-invasiveness (40); Hsp90 influences tumor 
neoangiogenesis stabilizing vascular endothelial growth factor in endothelial cells (41), 
Hsp27 overexpression plays an important role in metastasis in colorectal carcinoma (42) 
and Hsp60 has a role in metastasis in  head and neck squamous cell carcinoma (43). 
Moreover Hsps are expressed at higher levels in a wide range of cancers, compared to 
the normal tissutal counterpart, and they are closely associated with a poor prognosis 
and resistance to therapy. Hsps levels change during the carcinogenetic steps in various 
organs. For example, higher expression of Hsp60 was found in the adenoma-carcinoma 
sequence of the large bowel (44,45), in the dysplasia-carcinoma sequence of the uterine 
cervix (46) and during the carcinogenesis of prostate (47). 
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4. CHAPERONOPATHIES 
Chaperonopathies are pathological conditions associated with the impairment of one or 
more molecular chaperones. In this case the molecular chaperone malfunction is an 
etiological-pathogenic factor (21). The Chaperonopathies are classified etiologically as 
genetic or acquired and pathogenically as by defect, excess, or mistake. In genetic 
forms, the defective function of a chaperone is due to a gene mutation (21,48) Examples 
of genetic chaperonopathies are neurovegetative disease, congenital malformation, 
dilated cardiomyopathies, and endoplasmic reticulum pathologies (21). In acquired 
forms, the malfunction of a chaperone may be due to pathological post-translational 
modifications, such as oxidation, glycosylation and acetylation, causing alteration of 
function (21). Among the acquired chaperonopathies there are diseases associated with 
aging and with dysfunction of immune system (20). Usually, genetic chaperonopathies 
have an early onset, while acquired forms have an elderly onset. In the 
chaperonopathies classified into by defect, excess or mistake, the alteration is in the 
quantity of the chaperone and in its level and type of its function (48). In particular, the 
chaperonopathies by mistake or collaborationism are an important group of diseases in 
which a molecular chaperones may be normal, but participates in a pathological 
mechanisms that favors disease development, rather than defend the organism from the 
disease. Among these chaperonopathies, there are autoimmune disease and some types 
of tumors. For examples, in some autoimmune diseases (such as inflammatory bowel 
disease), the molecular chaperone may act as immunogenic and antibodies may 
generate against it. These antibodies would recognize the chaperone, now acting as 
antigen, and will react with it. In some cases this antigen-antibody interaction can 
stimulate an exaggerated immune response. A chaperone can also bind a receptor 
localized on the surface of immune cells (such as neutrophil and macrophage) and 
thereby triggers production of cytokines and starts inflammation (49). Finally, in some 
types of tumors, molecular chaperones can favors the survival of malignant cells in 
various ways, thus collaborating with the neoplastic process. The roles of chaperones in 
cancer are different depending on the type of tumor and vary going from supporting 
tumor growth and metastasis to participating in antitumor mechanism by promoting 
tumor-cell apoptosis (50). 
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5. EXOSOMES: A WAY FOR INTERCELLULAR 
COMUNICATION 
The intercellular communication is due to several mechanisms: cells can communicate 
with each other through soluble molecules that are in the extracellular environment 
(such as hormones and cytokines), through adhesion molecules that are localized on 
cellular surface (51), and through membrane vesicles released by one cell and captured 
by another. This mechanism of cellular communication is alternative and important 
because the extracellular vesicles can contain a large number of molecules that may 
transfer from one cell to another cell. The extracellular vesicles are constituted by a 
lipid bilayer that contains within different free proteins, as well as RNA and microRNA. 
Through different molecules present in their lumen, the vesicles could simultaneously 
activate different cellular pathways and can travel long distance before delivering their 
cargo between different cells within the organism (52). Based on their composition, size 
and mechanisms of release, extracellular vesicles have been named exosomes, apoptotic 
bodies, microvesicles, etc. Exosomes are a category of extracellular vesicles that have 
received most attention from researchers in this field. They have been implicated in 
different cellular functions and pathological conditions. Over the years they have been 
observed to be secreted into the extracellular medium from a large number of cell types, 
including T cells, B cells, dendritic cells, platelets, epithelial cells and cancer cells (53, 
54). Exosomes are 30-200 nm wide membranous vesicles first discovered in 1984 by 
Pan and Johnstone in maturing mammalian reticolocytes as a mechanism for removal of 
plasma membrane proteins (55). The secretion of exosomes is carried out in two steps 
divided as endocytosis and exocytosis. Initially, the exosome is formed inside the cell, 
in which a tract of plasma membrane bends inward. During this process, the proteins of 
membrane are incorporating into the internalized membrane, while cytosolic molecules 
are enclosed into the vesicles. In a second moment the vesicles formed by 
internalization of membrane, are enclosed into multivesicular endosomes (MVEs) that 
are vesicle larger and, after, fuse again with the plasma membrane and released into 
extracellular space as exosomes (56) (Fig.6). 
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Fig.6 Exosome biogenesis: a schematic view of the secretion of exosomes. The secretion of exosomes 
includes one step that consists in internalization of a portion of plasma membrane and formation of the 
multivesicular bodies (MVBs) The second step consists in the release of exosomes upon the fusion of 
MVBs with the plasma membrane. http://www.hindawi.com/journals/ijr/2012/573528.fig.001a.jpg 
 
Lipid rafts or cholesterol and sphingolipid microdomains, enriched in plasma 
membranes, are shown to play an important role in the formation of exosomes (57,58). 
These components give greater stability to the exosomes, which are collected from 
physiological fluids such as normal urine, plasma, synovial fluid (59, 60) Exosomes 
also contain common components such as chaperone (Hsc70), cytoskeletal proteins 
(such as actin and tubulin), endosomal sorting complexes required for transport 
(ESCRT) proteins (such as Alix). Depending on the cell types from which they are 
derived, exosomes play a role in diverse physiologic and pathological processes serving 
as a novel form of cell-cell communication. For example, different types of immune 
cells (such as antigen presenting cells, APCs, B cells and dendritic cells) secret 
exoxomes in which are present MCH I and II and stimulatory factors that induce the 
antigen-specific immune response. Tumor cells also produce exosomes, evidently 
abundant in culture and malignant effusions (61). Exosomes derived by tumor cells 
show anti-tumorigenic proprieties such as inducing tumor cell apoptosis (62) and 
promoting anti-tumor immunity (63) Many studies have, also, demonstrated that 
exosomes could play an important role in cancer progression (64) Cancer cell derided 
exosomes are related to the secretion of growth factors into tumor microenvironment. 
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The exosomes can carry factors that stimulate the proliferation of tumor cells, can favor 
the onset of metastasis (65) and can improve tumor angiogenesis (66) (Fig.7).  
 
Fig.7 A schematic picture that show the various functions in the intercellular cross-talk of exosomes. 
http://c431376.r76.cf2.rackcdn.com/17287/fonc-02-00038-HTML/image_m/fonc-02-00038-g001.jpg 
 
Exosomes derived by cancer cells can contain biomarker that could be important for the 
diagnosis or for the detection of pathological status. A study carried out on exosomes 
isolated from plasma derived by patients with ovarian cancer has demonstrate that these 
vesicles contain a protein that can be used, with other screening methods, for the 
detection of this cancer (67). Among the proteins that can be carried by exosomes there 
are Hsps. Hsp60 is present in the exosomes released from human tumor cell (54) and 
from cardiac myocytes in both basal state and following mild stress (68). Moreover, 
another study performed on exosomes derived from tumoral cells has shown that Hsp60 
is integrated in the exoxome membrane (32). These data suggest that a new role for 
extracellular Hsp60 in the cross talk between tumor cells and the immune system; in 
fact Hsp60 in exosome membrane would serve as a ligand for receptors of immune 
cells. The presence of Hsp60 in exosomes could also suggest a role of this protein as a 
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biomarker in assessing tumor progression. The molecular composition of exosomes 
reflects the specialized functions of the original cells (69). 
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AIMS 
The aims of this PhD thesis have been to evaluate:  
1) the levels and the expression of a number of HSPs, including Hsp60, in samples of 
human large bowel mucosa obtained from healthy controls (normal mucosa) and from 
patients with tubular adenomas with moderate grade dysplasia (preneoplastic lesion) 
and with adenocarcinoma with moderate grade differentiation (neoplastic lesion) by 
immunomorphology, WB and PCR;  
2) the subcellular localization of Hsp60 in normal and tumoral samples by immunogold 
experiments; 
3) the presence and the levels of circulating Hsp60 in the serum of patients with tumors 
before and after surgery, compared to controls, by ELISA; 
4) the presence and the levels of exosomal Hsp60 in the plasma of patients with tumors 
before and after surgery, compared to controls, by western blotting and other 
techniques. 
The first set of experiments (1) showed that Hsp60 is the most significant among the 
researched HSPs in terms of expression and levels, both in the epithelium and the 
lamina propria of pre-neoplastic and neoplastic lesions and this was why we continued 
our experiments (2,3,4) focusing only on this protein. 
Our intention was to (dis)prove the utility of Hsps, in particular Hsp60, in diagnostics, 
assessing the prognosis and follow-up in patients affected by colorectal neoplastic 
lesions. Moreover, our results should shed light on the usefulness of Hsp60 as target for 
a novel anti-cancer approach (chaperonotherapy) given its putative involvement in 
colorectal carcinogenesis. 
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EXPERIMENTAL PROCEDURES 
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1. Specimen collection 
Formalin-fixed paraffin embedded biopsies of tubular adenomas with moderate grade of 
dysplasia (n°20) were retrospectively collected from files of the Surgical Anatomy Unit 
of the Civico Hospital, Palermo, Italy, for histological and immunomorphological 
analyses.  
Tissue biopsies from 40 large bowel mucosa of healthy controls (n°20) and 
adenocarcinomas with a moderate grade of differentiation (n°20) were collected 
prospectively for histological and immunomorphological analyses, western blotting and 
PCR analysis. The samples for histological and immunomorphological analyses were 
fixed in formalin and included in paraffin, while the samples for Western Blotting and 
PCR analyses  were kept frozen at -80°C until use.  
Tissue samples from 10 colon adenocarcinomas (G2) were collected for the evaluation 
of sub-cellular/sub-tissutal localization of HSP60 (by immunogold) with transmission 
electron microscopy (TEM).  
Two blood samples from 20 patients with colon adenocarcinomas (G2) were also taken, 
the first one day prior to, and the second one week after, the surgical removal of the 
tumor; at the same time we collected blood samples from 20 healthy age-matched 
controls. Plasma was obtained from these samples to perform, respectively, ELISA test 
and exosome isolation.  
All these biopsies were obtained from the DICHIRONS Department of the University 
of Palermo, Italy. All the procedures were in accordance with the ethical standards of 
the responsible committees (institutional and national) on human experimentation and 
with the Helsinki Declaration of 1975 (as revised in 2008). Written informed consents 
were obtained from all patients at the time of biopsy and blood sampling, and the study 
was approved by Ethics Committee of the Polyclinic Hospital of the University of 
Palermo, Italy. 
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2. Histological analysis 
For histological analysis, the samples were fixed in formalin and embedded in paraffin. 
From all paraffin blocks sections with a thickness of 4–5 mm were obtained with a 
cutting microtome. These sections were dewaxed in xylene for 10 minutes and 
rehydrated by sequential immersion in a descending scale of alcohols and transition in 
water for five minutes. The sections were then stained with hematoxylin and eosin, 
mounted with coverslips and finally, observed with an optical microscope (Leica DM 
5000 B) connected to a digital camera (Leica DC 300F).  
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3. Immunohistochemistry  
Immunohistochemistry was performed on 5-micron thick sections of paraffin-embedded 
tissue, arranged with the microtome.  The sections were dewaxed in xylene for 30’ at 
60°C and rehydrated, at room temperature, by sequential immersion in a graded series 
of alcohols and transferred into water for five minutes. Subsequently, the sections were 
immersed for 8' in Sodium Citrate Buffer (pH 6) at 95°C for antigen retrieval and, 
subsequently, immersed for 8’ in aceton at -20°C to prevent the detachment of the 
sections from the slide. All subsequent reactions were conducted at room temperature. 
After a wash with PBS (Phosphate Buffered Saline pH7.4) for 5’, the sections were 
treated for 5’ with Peroxidase Quencing Solution (reagent A of Histostain®-Plus 3rd 
Gen IHC Detection Kit, Invitrogen) to inhibit any endogenous peroxidase activity. 
Another washing with PBS for 5’ was carried out and the sections were treated with a 
blocking protein (reagent B of Histostain®-Plus 3rd Gen IHC Detection Kit, Invitrogen) 
for 10’ to block non-specific antigenic sites. Subsequently, the sections were incubated 
overnight, with a primary antibody against human Hsp10 (Gene Tex polyclonal, 
dilution 1:300), human Hsp60 (mouse anti-Hsp60 monoclonal antibody, Sigma, St. 
Louis, MO, catalogue no. H4149, dilution 1:400), human Hsp70 (SANTA CRUZ 
BIOTECHNOLOGY, clone W27, dilution 1:200) and human Hsp90 (SANTA CRUZ 
BIOTECHNOLOGY, clone F-8, dilution 1:200). Appropriate positive and negative 
(isotype) controls, were run concurrently. After a wash with PBS (Phosphate Buffered 
Saline pH7.4) for 5’, the sections were incubated with a universal biotinylated 
secondary antibody (Biotinylated Secondary Antibody reagent C Histostain®-Plus 3rd 
Gen IHC Detection Kit, Invitrogen) for 10’. After a subsequent washing with PBS for 
5', the sections were incubated with streptavidin-peroxidase complex (Streptavidin-
Peroxidase Conjugate reagent D Histostain®-Plus 3rd Gen IHC Detection Kit, 
Invitrogen) for 10', and following a further washing in PBS for 5', the slides were 
incubated in the dark for 5' with the DAB chromogen (diaminobenzidine) (DAB 
chromogen reagents E1 and E2 Histostain®-Plus 3rd Gen IHC Detection Kit, 
Invitrogen). Nuclear counterstaining was carried out using hematoxylin (Hematoxylin 
aqueosus formula, N. Cat. S2020, DAKO). Finally, the slides were prepared for 
observation with coverslips with an aqueous mounting solution. The observation of the 
sections was performed with an optical microscope (Leica DM 5000 B) connected to a 
digital camera (Leica DC 300F). 
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4. Western Blotting 
50mg of tissue samples from normal mucosa and colon adenocarcinoma were incubated 
on ice in a RIPA lysis buffer (0.3M NaCl, 0.1% SDS, 25mm HEPES pH 7.5, 1.5mm 
MgCl2 , 0.2 mm EDTA, 1% Triton X-100, 0.5mm DTT, 0.5% sodium deoxycholate) 
containing proteases and phosphatase inhibitors (0.1 mg/ml phenylmethyl sulfonyl 
fluoride, 20 mg/ml aprotinin, 20 mg/ml leupeptin, 10 mg/ml NaF, 1 mM DTT, 1 mM 
sodium orthovanadate, 20 mM ß-glycerol phosphate) for 1 h. Subsequently, the samples 
were centrifuged at 13,000 rpm for 10' at 4°C and supernatants were isolated. Protein 
concentration was measured by the Bradford method. Proteins (40 mg) were separated 
on a 12% SDS-PAGE gel. The separated proteins were electrophoretically transferred to 
a nitrocellulose membrane (Hybond-C Extra, Amersham Biosciences, GE Healthcare, 
Little Chalfont, England (Nitrocell Paper, Bio-Rad). Equal protein loading was 
confirmed by Ponceau-S staining of the blotted membranes. After 1hr incubation at 
room temperature with a blocking solution, 5% milk (Target Retrieval Solution, 
DAKO) in TBS with 0.05% Tween 20 (Polyoxyethylene sorbitan monolaurate, Sigma-
Aldrich) (T-TBS), the membranes were incubated with primary antibodies (rabbit anti-
Hsp10 polyclonal antibody, Gene Tex; mouse anti-HSP60, LK1 clone, Sigma-Aldrich; 
mouse anti-Hsp70, W27 clone, SANTA CRUZ BIOTECHNOLOGY; mouse anti-
Hsp90, F-8 clone, SANTA CRUZ BIOTECHNOLOGY) diluted 1:1000 in T-TBS 
containing 1% dry milk. Blots were washed in T-TBS and incubated for 1 h with HRP-
conjugated secondary antibodies (ECLTM anti-mouse IgG HRP-conjugated whole 
antibody; ECLTM anti-rabbit IgG HRP-conjugated whole antibody, Amersham 
Biosciences) diluted 1:8000 in T-TBS containing 1% dry milk. The final detection 
procedure was carried out using the ECL Western Blotting Detection Reagent 
(Amersham Biosciences) according to the manufacturer’s instructions. Band analysis 
was performed with the ImageJ 1.41 software (National Institutes of Health, USA, 
http://rsb.info.nih.gov/ij). 
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5. Total RNA extraction 
Total RNA extraction from all tissue samples was performed using TRIzol® 
REAGENT (Sigma-Aldrich, USA), a mixture of guanidine thiocyanate and phenol in a 
mono-phase solution that dissolves RNA on homogenization of tissue sample. Tissue 
samples were then homogenized in TRI REAGENT (1ml for 50-100 mg of tissue) and 
subsequently centrifuged at 12000 x g for 10 minutes at 4°C to remove the insoluble 
material. 0,2 ml of chloroform was then added to the samples. After 15 minutes, the 
mixtures were centrifuged at 12000 x g for 15 minutes at 4°C, to separate the RNA 
(aqueous phase) from proteins and DNA. Subsequently, the aqueous phase was 
transferred to a fresh tube to which 0,5 ml of isopropanol was added. After 10 minutes, 
the samples were centrifuged at 12000 x g at 4°C. The supernatant was removed and the 
RNA pellet was added to 1 ml of 75% ethanol and then shaken. The mixture was 
centrifuged at 7500 x g for 5 minutes at 4°C. The RNA was eluted from the filter in 
50μl of RNase-free H2O. The RNA extract obtained was stored at -20 ° C until use. The 
concentration of the RNA extracts was determined by spectrophotometer with a 
wavelength of 260nm. Only samples with an A260/A280 ratio of over 1.8-2 were 
considered usable for the following analyses. 
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6. RT-PCR (Reverse Transcription Polymerase Chain Reaction) 
Qualitative RT-PCR was performed using ImProm –II Reverse Transcriptase (Promega) 
for the RNA retrotranscription, and GoTaq Flexi DNA Polymerase for the amplification 
of cDNA. For RNA retrotrascription, the reaction was performed according to the 
manufacturer’s instructions. The RT reactions were cycled at 25°c for 5 minutes for 
annealing, at 50°C for 60 minutes for extension, and at 70° C for 15 minutes for 
inactivation of reverse trascriptase. PCR amplification was performed by adding 
specific primers for human Hsp60, Hsp10, Hsp70, Hsp90α and Hsp90β (for Hsp60 
cDNA, the forward primer sequence was 5'-CGACGACCTGTCTCGCC- and the 
reverse primer sequence was 5'CTTTGGCATAAGCCCGAGTG-3'; for Hsp10 cDNA, 
the forward primes sequence was 5'CTCCCAGAATATGGAGGCACC-3' and the 
reverse primes sequence was 5'-TGGAATGGGCAGCATCATGT-3'; for Hsp70 cDNA, 
the forward primer sequence was 5'-AAAGATGGACCAACCACCCC-3' and the 
reverse primer sequence was 5'-CCTCCACTGCGTTCTTAGCA-3'; for Hsp90α cDNA, 
the forward primer sequence was 5'-GTCTAGTTGACCGTTCCGCA-3' and the reverse 
primer sequence was 5'-GAGGAGGCACCCTCAAGTTC-3'; for Hsp90β cDNA, the 
forward primer sequence was 5'-CTCTCTCGAGTCACTCCGGC-3' and the reverse 
primer sequence was 5'-GTACGTTCCTGAGGGTTGGG-3'). The reactions were 
cycled at 95°C for 2 minutes (1 cycle) for initial denaturation; at 95° C for 1 minute for 
denaturation, at 63-59,4 °C for 1 minute for annealing, at 72°C for 1 minute for 
extension (25 cycles), followed by a final extension at 72°C for 5 min (1 cycle).  
Finally, the PCR product was visualized on 1.5% agarose gel with the Syber stain 
(SYBER SafeTM DNA gel stain, Invitrogen). 
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7. ELISA Assay for Human Hsp60 
ELISA was performed as previously described (70) using a commercial Hsp60 (human) 
enzyme immunoassay (EIA) kit (ADI EKS 600 ELISA kit from Enzo Life Sciences, 
Inc., Farmingdale, NY, USA). Blood samples from 20 patients with colon 
adenocarcinoma (G2) and 20 healthy age-matched controls were collected in EDTA-
treated tubes. After a centrifugation at 2,000×g for 10 min, plasma was collected, 
aliquoted, and stored at −20 °C until use. A monoclonal mouse antibody for Hsp60 was 
pre-coated on the wells of anti-HSP60 Immunoassay plates. All reagents were used at 
24°C and the standard Hsp60 was diluted in a sample diluent to perform a standard 
curve with six points, ranging from 3,125 to 100 ng/mL. Sample diluent alone was used 
as 0 (zero) standard. Primarily, 100µL of prepared standards and serum was added in 
duplicate to wells in incubation at 24°C for 1h. After washing six times with 1 x Wash 
buffer, 100µL of diluent anti-Hsp60 goat polyclonal antibody was added to each well 
and incubated at 24°C for 1h. After, 100µL of diluent horseradish peroxidase-conjugate 
anti-goat IgG was added to the plate and incubated at 24°C for 30 minutes. After 
washing, 100µL of 3,3′,5,5′-tetramethylbenzidine substrate was added and incubated for 
15 min in the dark. Finally, 100 μL of Stop Solution was added and absorbance was 
measured at 450 nm in a microplate photometric reader (DV990BV4, GDV, Milan, 
Italy). Sample concentration was calculated by interpolating the sample concentrations 
in the standard curve. The sensitivity of the Hsp60 (human) EIA was determined to be 
3.125 ng/mL. The intra-assay coefficient of variation of Hsp60 (human) EIA was 
determined to be <10% and the inter-assay coefficient of variation was also determined 
to be <10%. 
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8. Transmission electron microscopy (TEM). 
8.1 LR-White inclusion 
Samples of large bowel adenocarcinoma were fixed for 1 hour in 4% paraformaldehyde. 
Subsequently, the samples were washed in Millonig's buffer and stored in the buffer 
until they were processed. The samples were dehydrated with ascending methanol series 
(30, 50, 70, and 100%). Each step was repeated two times for 20 minutes. The samples 
were then treated with a solution of LR-white methanol two times for 30 minutes. 
Following this step, the samples were left in pure resin at 4°C overnight. Next day, the 
LR-WHITE resin was put into the accelerator and the specimens were subsequently put 
in embedding containers in LR-WHITE resin for 24 hours at 60°C. 
8.2 Immunogold 
Ultrathin sections, obtained by cutting the LR-WHITE resin blocks with an 
ultramicrotome, were mounted on gold grids to prepare them for the immunogold assay.  
The grids were washed for three times with distilled water, and incubated with 
hydrogen peroxide (0,3%) for 10 minutes. After washing twice in PBS, the grids were 
incubated in a serum blocking solution for 30 minutes and, without washing, the 
incubation was continued with a primary antibody diluted in a dilution buffer for 1 hour 
at room temperature. The primary antibody used was against Hsp60 and diluted at 1:15. 
Grids were rinsed three times with PBS for 5 min and incubated with a secondary 
antibody conjugated with 10nm colloidal gold particles for 30 minutes at room 
temperature. Subsequently, the grids were washed again for three times with PBS for 5 
minutes and then fixed in a 2% glutaraldehyde solution in PBS for 10 minutes followed 
by three washings in distilled water for 5 minutes. The grids were then prepared for 
contrast staining by treating them with uranyl acetate (1%) for 5 minutes, followed by 
eight washings with methanol for 2 minutes, and treated with Reynolds' solution for 5 
minutes and finally rinsed eight times in distilled water for 2 minutes. After this 
procedure, the grids were ready for electron microscopy (JEOL JEM 1220 TEM at 
120kV). 
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9. Exosome isolation from plasma 
Exosomes were isolated from plasma as previously described (71) with minor 
modifications. Blood samples of 20 patients (drawn one day prior to, and one week after 
surgical removal of the tumor) and 20 healthy controls were treated with EDTA and 
centrifuged at 4000 x g for 5 minutes and 11000 x g for 10 minutes and 20 minutes to 
separate the plasma. Samples were diluted with PBS and another centrifugation at 
29,500 X g for 20 min was performed to pellet any remaining cells and debris. The 
supernatant was then filtered through a 0.2 µm filter (Millex GP, Millipore), followed 
by ultracentrifugation at 110,000 X g for 2 hrs to pellet the exosomes. The exosomes 
were then washed in cold PBS and resuspended in 50 µl of PBS. 
9.1 Exosomes assessment procedure 
To further ascertain the identity of the exosomes obtained from the plasma of the blood 
samples, exosomal preparations were examined by TEM and tested for markers 
considered characteristic of exosomes (Acetylcoline esterase activity, presence of Alix 
and Hsc70 proteins). 
An assessment of exosome quality by transmission electron microscopy (TEM) was 
performed to ascertain the diameter of exosomal vesicles, which should be 100 nm or 
less (58,72). Pellets obtained by ultracentrifugation were resuspended in PBS with the 
addition of 100µl of freshly made fixative (2,5% glutaraldehyde in PBS) for 30 minutes. 
After fixation, the preparations were mounted on formvar nickel grids by layering grids 
over 10 ml drops of exosome preparations for 10 minutes at 24°C. Grid-mounted 
preparations were prepared for contrast staining by treating them with uranyl acetate 
(1%) for 5 minutes and with Reynolds’ solution for 5 minutes and, finally, rinsing them 
eight times in distilled water for 2 minutes. After this procedure, the grids were ready 
for electron microscopy (JEOL JEM 1220 TEM at 120kV). 
The assessment of exosome quality by acetylcoline esterase assay was performed to 
determine whether the vesicles purified showed Achetylcoline Esterase that is typically 
detected in exosomes (73). 15µl of the exosomal preparations were suspended in 100µl 
of PBS and incubated with acetylcoline (1,25mM) and 5,5'-dithio-bis-(2-nitrobenzoic) 
acid (0,1 mM) in a final volume of 1 ml. The incubation was performed in cuvettes at 
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37°C. The change in absorbance at 412 nm was monitored every 5 minutes for 30 
minutes by a plate reader. 
The assessment of exosome quality by identification of Alix and Hsc70 proteins was 
performed by Western Blotting analysis carried out on the exosomes purified by 
ultracentrifugation.  For the Western Blotting analyses, 10µl (O 80µg) of exosome 
preparations were used, and the primary antibody used for Alix (mouse anti-Alix, 1A12 
clone, SANTA CRUZ BIOTECHNOLOGY, INC, Santa Cruz, CA, USA, n° catalogue 
sc-53540) was diluted at 1:500 while the one for Hsc70 (mouse anti-Hsc70, B-6 clone, 
SANTA CRUZ BIOTECHNOLOGY, INC, Santa Cruz, CA, USA, n° catalogue sc-
7298) was diluted at 1:500. The analysis was performed following the procedure 
described above (see paragraph n.4). 
9.2 Western Blotting analysis of Hsp60 in Exosomes   
10µl (O 80µg) of exosome preparations were used for western blotting analysis and a 
primary antibody for Hsp60 (mouse anti-HSP60, LK1 clone, Sigma-Aldrich) diluted at 
1:1000 was used to detect the presence of Hsp60 in plasma exosomes. The analysis was 
performed following the procedure described above (see paragraph n.4). 
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10. Double immunofluorescence on adenocarcinoma tissue 
Formalin fixed, paraffin-embedded sections of colorectal adenocarcinoma were run for 
the double immunofluorescence experiments. These experiments were two: the first was 
performed using primary antibodies anti-Hsp60 and anti-CD68, a marker for 
macrophages; the second was performed using primary antibody anti-Hsp60 and anti-
CD34, a marker for endothelial cells. After dewaxing in xylene, rehydration in ethanol, 
and washing in phosphate-buffered solution (PBS), sections were incubated with 
unmasking solution (tri-sodium citrate 10 mM, 0.05%Tween 20) for 10 min at 58 °C 
and treated with blocking solution (3 % albumin bovine serum in PBS) for 30 min at 23 
°C. Then, the sections were incubated with the first primary antibody (rabbit polyclonal 
antihuman HSP60, Clone H300, SANTA CRUZ BIOTECHNOLOGY, INC, Santa 
Cruz, CA, USA, catalogue n° sc-13966) diluted 1:100, overnight at 4 °C. The day after, 
the sections were incubated with the second primary antibody (For first experiment 
Mouse Monoclonal anti-CD68, clone KP1,  SANTA CRUZ BIOTECHNOLOGY, INC, 
Santa Cruz, CA, USA, catalogue n° sc-20060 and for second experiment Mouse 
Monoclonal anti-CD34, clone B-6, SANTA CRUZ BIOTECHNOLOGY, INC, Santa 
Cruz, CA, USA, catalogue n° sc-74499) diluted 1:100, overnight at 4 °C. After washing 
twice in PBS all sections were incubated with fluorescent secondary antibodies such us 
rabbit IgG antibody conjugated with Texas Red (diluted 1:200; Gene Tex Inc, Irvine, 
USA) and mouse IgG antibody conjugated with fluorescein isothiocyanate (FITC; 
diluted 1:200; Sigma-Aldrich, Milan, Italy) respectively. The nuclei were 
counterstained with Hoechst (Sigma-Aldrich, Inc, Milan, Italy) for 15 min at 23 °C. 
Finally, all slides were mounted with cover slips using a drop of PBS, and readings and 
imaging were immediately performed with a Leica DM5000 upright fluorescence 
microscope (Leica Microsystems, Heidelberg, Germany). The cell positivity of both 
markers (“Merge”) was assessed through the program Adobe Photoshop CS5 version 
12.0.4x64. 
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11. Statistical analyses 
Statistical analyses were carried out using the GraphPad Prism 4.0 package (GraphPad 
Inc., San Diego, CA, USA). Standard statistical analyses were employed to calculate the 
means and the standard deviations (SD). One-way ANOVA (and nonparametric) 
analysis of variance was used to assess significant differences within the data. 
Differences between the means were considered significant when P<0.001 as indicated 
in the figures. 
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RESULTS 
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1. Histological analysis 
Histological analysis was carried to group the samples before further experiments. 
Three groups of samples were set up (1: normal mucosa; 2: tubular adenoma with 
moderate dysplasia; 3: adenocarcinoma with a moderate grade of differentiation) 
(Fig.8). 
 
 
 
 
Fig. 8 Representative pictures of hematoxylin and eosin staining A)Normal mucosa of colon; B) 
Adenoma with moderate dysplasia of colon; C) Adenocarcinoma with moderate grade of differentiation 
of colon. Magnification 200x. Scale bar: 100µm. 
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2. Immunohistochemical analysis 
The immunohistochemical evaluation was carried out on all samples of normal mucosa, 
tubular adenoma and colon adenocarcinoma. Cellular expression of Hsp10 and Hsp90 
was cytoplasmic and sometimes granular. Hsp60 immunopositivity was visible at 
cytoplasmic and membrane levels, while Hsp70 immunopositivity was visible at 
cytoplasmic and nuclear levels. The levels of expression of Hsps were investigated in 
the epithelium and lamina propria cells. The percentage of positive cells was calculated 
in 10 random high power fields (HPF) at a magnification of 400x, and was expressed as 
means (See Table 2). The immunohistochemical reactions show that Hsp60 and Hsp10 
expression levels, both in the epithelium and lamina propria, increase gradually 
throughout the carcinogenic steps of large bowel cancer, from normal mucosa through 
tubular adenoma with moderate dysplasia to invasive adenocarcinoma (G2). Hsp70 
immunopositivity levels increase significantly only in the epithelium of invasive 
adenocarcinoma, compared to normal and dysplastic mucosa. No change is detectable in 
the lamina propria. Finally, Hsp90 levels increase significantly only in the lamina 
propria cells of invasive adenocarcinoma, compared to normal and dysplastic mucosa, 
while the epithelium shows no changes (Fig.9). Data obtained from 
immunohistochemistry evaluations were plotted using Microsoft Excel software 
(Microsoft Italia, Milan, Italy). Statistical analyses were carried out using the GraphPad 
Prism 4.0 package (GraphPad Inc., San Diego, CA, USA). Standard statistical analyses 
were employed to calculate the means of percentage positivity and the standard 
deviations (SD) (Fig.10). 
 
 
Immunostaining NM AT AC 
EC 
% 
LPC 
% 
EC 
% 
LPC 
% 
EC 
% 
LPC 
% 
Hsp10 48,5 2,1 67,5 6,2 90 10 
Hsp60 6 1,9 65 5 95 10 
Hsp70 30 3,5 30 3,5 65 5 
Hsp90 70 30 75 25 78 40 
 
Table 2: Results of immunohistochemical evaluations expressed as average percentage in Epithelial Cells 
(EC) and Lamina Propria Cells (LPC) in the groups of Normal Mucosa (NM), Tubular Adenoma (TA) 
and Adenocarcinoma (AC) of colon. The percentage of positive cells was calculated in 10 random high 
power fields (HPF) at a magnification of 400x, and was expressed as means. 
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Fig. 9 Representative pictures of immunohistochemical experiments performed for Hsps in samples of 
large bowel human mucosa. Hsp10 immunostaining: A) Normal Mucosa; B) Tubular Adenoma with 
moderate grade of dysplasia; C) Adenocarcinoma with moderate grade of differentiation. Hsp60 
immunostaining: D) Normal Mucosa; E) Tubular Adenoma with moderate grade of dysplasia; F) 
Adenocarcinoma with moderate grade of differentiation. Hsp70 immunostaining : G) Normal Mucosa; H) 
Tubular Adenoma with moderate grade of dysplasia; I) Adenocarcinoma with moderate grade of 
differentiation. Hsp90 immunostaining: L) Normal Mucosa; M) Tubular Adenoma with moderate grade 
of dysplasia; N) Adenocarcinoma with moderate grade of differentiation. Magnification 200x. Scale bar 
100µm. 
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Fig. 10 Histograms show statistical results for the evaluation of immunopositivity for Hsp10, Hsp60, 
Hsp70 and Hsp90 in epithelial cells (upper histogram) and in cells of lamina propria (lower histogram) in 
samples of normal mucosa (NM), tubular adenoma(TA) and Adenocarcinoma (AC) of human large 
bowel. 
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3. Western Blotting analysis 
Western Blotting experiments were carried out on samples of normal mucosa and 
adenocarcinoma of colon. The results obtained by these analyses have showed that 
Hsp10, Hsp60, Hsp70 and Hsp90 levels increase significantly from normal mucosa to 
adenocarcinoma (Fig.11). Densitometric analysis of blots was performed using the NIH 
Image J 1.40 program (National Institutes of Health, Bethesda, MD,USA) (Fig.12). The 
data resulting by western blotting experiments are in agreement with the 
immunohistochemical results. 
 
Fig. 11 Representative immunoblots of western blotting analysis for Hsp10, Hsp60, Hsp70, Hsp90 in 
Normal Mucosa (NM) and Adenocarcinoma (AC). β-actin was used as a loading control. 
 
 
Fig. 12 Densitometric quantification of Hsp10, Hsp60, Hsp70 and Hsp90 protein levels in Normal 
Mucosa (NM) and Adenocarcinoma (AC). 
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4. RT-PCR (Reverse Transcription Polymerase Chain Reaction) 
RT-PCR experiments were carried out on samples of normal mucosa and 
adenocarcinoma of colon. The results obtained by RT-PCR analyses have showed that 
mRNA expression levels of Hsp10, Hsp60, Hsp70, Hsp90α and Hsp90β are higher in 
samples of adenocarcinoma than normal mucosa (Fig.13). Quantitative measurements 
of bands were performed using the NIH Image J 1.40 analysis program (National 
Institutes of Health, Bethesda, MD, USA) (Fig.14).  These data suggest that increased 
levels (as shown by IHC and WB) are due to an increased gene expression of these 
molecules. 
 
 
Fig. 13 1.5% agarose gels of the gene HSP10, Hsp60, Hsp70, Hsp90 isoform α and Hsp90 isoform β from 
Homo sapiens amplified by RT-PCR. 
 
 
 
Fig. 14 Histogram of quantitative measurements of bands of mRNA expression levels for Hsp10, Hsp60, 
Hsp70, Hsp90α,Hsp90β genes. 
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5. ELISA Assay for Human Hsp60 
ELISA assay carried out on serum of 20 patients with adenocarcinoma and 20 healthy 
subjects has showed significantly (p<0,001) higher levels of Hsp60 in patients with 
colon cancer compared to healthy controls. However, one week after surgical removal 
of the tumor, Hsp60 levels significantly decreased reaching those of healthy subjects. 
The mean of Hsp60 plasma levels in healthy controls was 4,94 ng, in patients with 
colon adenocarcinoma was 31,45 ng in blood samples taken 1 day before surgical 
remove of tumor and, 3,2 ng  in blood samples taken 1 week after surgical remove of 
tumor (Fig.15).  
 
 
 
 
Fig. 15 Histogram of Hsp60 plasma levels by Elisa Assay (ADI EKS 600 ELISA kit, Enzo Life Sciences, 
Inc., Farmingdale, NY, USA) 
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6. Immunogold experiments by Transmission electron microscopy 
(TEM) 
Immunogold experiments were carried out to obtain a better ultrastructural localization 
of Hsp60 in adenocarcinoma tissue. Figure 16 shows that, in colon cancer cells, Hsp60 
(black dots) is localized not only in the mitochondria (Fig.16 D) but also in the cytosol, 
in cytoplasmic regions very close to the membrane (Fig.16 B) and, to a large extent, 
also in the plasma membrane (Fig.16 A, C). These data suggest an active trafficking of 
Hsp60 in the cellular regions between the membrane and the neighboring areas of the 
cytoplasm. 
 
 
 
 
Fig. 16 Immunogold stains for Hsp60 (black dots) in large bowel adenocarcinoma’s tissue. A) Hsp60 
localization in the membrane of adenocarcinoma cells. Bar: 1 µm B) Hsp60 localization in the cytosol 
very close to, and on the plasma membrane. Bar: 100nmC) Hsp60 localization on the cell membrane. 
Bar: 100nm. D) Hsp60 localization in the cytoplasm of cancer cells. Bar: 100nm.  
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7. Exosomes assessment procedure 
To further ascertain the identity of the exosomes isolated from plasma samples, 
exoxomal preparations were examined by transmission electron microscopy (TEM). 
TEM analysis showed that the vesicles contained in the pellet isolated from plasma, 
were compatible with typical exosomes because presented the ultrastructural hallmarks 
of exosomes. Vesicles present in the pellet were of 30-90 nm in diameter (Fig.17). 
 
Fig.17 Demonstration by TEM of exosomal preparation. An illustrative image of the exosomes isolated 
from plasma. Bar: 100nm. 
                                   
Moreover the exosomal preparations were tested for Acetyl cholinesterase (AChE) 
activity that is typically detected in exosomes. Results obtained by AChE assay, 
confirmed the presence of exosomes in the pellet of ultra-centrifuged samples. In fact, 
the exosomes purified by ultra-centrifugation of plasma, showed an AChE activity that 
increased over the observation period of 30 minutes. In contrast the supernatant of 
ultracentrifugation products, showed very low AChE activity. Data are represented as 
mean ± SD of AChE activity measured at 412 nm every 5 minutes for 30 minutes in 
three independent experiments in duplicate (Fig.18). 
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Fig.18 AChE activity assay in exosomal preparations from the pellet and supernatants obtained after 
ultra-centrifugation of plasma. 
 
             
Finally the Western Blotting analyses performed for Alix protein and Hsc70 protein, 
showed the presence of these markers in the pellet obtained from ultra-centrifugation 
(Fig.19). 
                             
 
Fig.19 Demonstration of Hsc70 and Alix poteins by Western Blotting in exosomal preparation. 
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8. Western Blotting analysis for Hsp60 in Exosomes 
Western Blotting experiments for Hsp60 in exosomes showed that this protein was 
present in the exosomes isolated from the plasma of 20/20 patients with 
adenocarcinoma of colon (G2) before surgery. Its levels decrease significantly, in the 
same patients, one week after surgical removal of the tumor (Fig.20). While, Hsp60 was 
present in exosomal fraction of 1/20 healthy control (data not shown).  These data are in 
agreement with the immunohistochemical results. Densitometric analysis of blots was 
performed using the NIH Image J 1.40 program (National Institutes of Health, 
Bethesda, MD,USA) (Fig.21). 
   
 
Fig.20  Hsp60 was present in the exosomes 
isolated from the plasma before surgery (BS). Its 
levels decrease significantly one week after 
surgical removal of the tumor (AS). 
 
      
 
 
Fig.21 Histograms show statistical results for the evaluation of Hsp60 levels in the exosomes isolated 
from plasma.  
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9. Double immunofluorescence analysis 
Double immunofluorescence experiments for Hsp60 and CD68 performed on 
adenocarcinoma tissue sections, revealed that Hsp60 (red color) was present in almost 
all cancer cells and, also, in most of macrophages of the lamina propria that showed a 
double positivity for Hsp60 and CD68 (orange color) (Fig.22). 
 
 
Fig.22 Double immunofluorescence for Hsp60 and CD68: Hsp60 (red) was expressed in almost cancer 
cells, and also in most of macrophages (arrows on green-orange cells). Magnification 200x. Bar 100µm. 
Below and to the left of the figure shows a macrophage that presents a double positivity for Hsp60 (red 
color) and for CD68 (green color). The result of color merge is orange. Magnification 630x. 
 
 
 
 
 
 
Double immunofluorescence for Hsp60 and CD34 showed that Hsp60 was present in 
almost cancer cells (red color). CD34 was expressed in the endothelial cells of the 
vessels of the lamina propria (green color). Hsp60 was expressed also in most of 
endothelial cells (that expressed a double positivity for Hsp60 and CD34) (Fig.23). 
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Fig.23 Double immunofluorescence for Hsp60 and CD34: Hsp60 (red color) was expressed in almost 
cancer cells. CD34 was expressed in the endothelial cells of the vessels of the lamina propria (green 
color). Arrows are on lamina propria vessels. Magnification 200x. Bar 100μm. Below and to the left of 
the figure shows a vessel with endothelial cells positive for both markers Hsp60 (red color) and CD34 
(green color). Magnification 630x. 
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6. DISCUSSION 
Many reports support the idea that Hsps are implicates in the pathogenesis and in the 
progression of different human neoplasms, by uncertain metabolic mechanisms. 
Although Hsps perform their canonical “chaperoning” functions in both prokaryotic and 
eukaryotic cells, they have also acquired, probably during evolution, “extra-
chaperoning” roles. Among these roles, there are some involved in the mechanisms of 
cancerogenesis of many types of cancers, as discussed in the Introduction section.  
In this PhD thesis, we have been studies the protein expression of some Hsps (in 
particular Hsp10, Hsp60, Hsp70 and Hsp90) through experiments of 
immunohistochemistry in samples of human mucosa of large bowel taken from normal 
controls, pre-neoplastic lesions and invasive neoplasms. The results obtained have 
shown that Hsp10 and Hsp60 expressions are higher in pre-neoplastic lesion as well as 
in cancer lesion compared to normal mucosa. By contrast, Hsp70 and Hsp90 levels were 
increased only in the tumoral specimens, while there was not any difference between 
normal and preneoplastic lesions for these proteins. High levels of Hsp10 in the 
cytoplasm of cancer cells have been reported in the past (46) Also, Hsp60 has been 
shown to be overexpressed and localized in the cytoplasm of cancer cells (44). Hsp70 
levels have shown an increase in expression only in epithelial component of cancer 
samples, and their immunohistochemical expression was localized in the cytoplasm and 
in the nucleus of cancer cells compared with normal cells. Hsp90 expression has shown 
only few significant differences between the samples studies, i.e.  at the lamina propria 
levels of the tumoral component.  
Hsp60 and Hsp10 are classically considered a mitochondrial molecule, while Hsp70 and 
Hsp90 are commonly present in the cytosol. The observation of an immunopositivity of 
Hsp60 at the cytoplasmic and membrane levels, as well as a nuclear immunopositivity 
of Hsp70 in cancer cells, confirms the concept that Hsps may change their intracellular 
distribution in comparison with normal cells. The presence of a diffuse 
immunohistochemical positivity for Hsp60 in the cytoplasm and on the plasma 
membrane and for Hsp70 in the nucleus have already been described in other forms of 
tumors (50,74,75) and have been correlated with tumor progression. These data indicate 
that the change of localization of Hsps in the cell may be an important marker of tumor 
progression. The immunoistochemical data obtained in this work were confirmed by 
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western blotting experiments that have shown increasing protein levels of all Hsps 
studied in the samples of invasive cancer compared with the samples of normal mucosa. 
Moreover the data obtained from the RT-PCR analyses conduct for Hsp10, Hsp60, 
Hsp70, Hsp90α and Hsp90β suggest that increased levels (as shown by IHC and WB) 
are due to an increased gene expression of these molecules. For the WB and RT-PCR 
experimental procedures, tubular adenoma biopsy samples were not used for two 
reasons. The main reason is that tubular adenoma is a dysplastic lesion that must be 
histologically evaluated as a whole. The second reason is that the characteristic presence 
of alternating normal and dysplastic glands within the same lesion may produce biased 
results.  
The results obtained from the comparative evaluation of protein levels and genic 
expressions of Hsps have confirmed higher level of expressions of these proteins in the 
adenocarcinoma of colon. However, the limit of these techniques is that it does not 
permit to differentiate among levels of molecules and RNA in the different component 
of the tissues, i.e., epithelial and lamina propria components. However, these data are in 
agreement with many reports that have found changes of Hsps levels during the 
carcinogenetic process in various organs, such as oral cavity (76), uterine cervix (77), 
prostate (47) and large bowel (45). These evaluations imply that the all these Hsps are 
involved, directly or indirectly, in the carcinogenesis of these types of tumors.  
However, the increased levels of Hsp60 and Hsp10 also in preneoplastic lesions led us 
to hypothesize that these molecules are involved in the very early step of the 
carcinogenesis of this anatomical district.  
Since other studies already showed in vitro that Hsp60 may be secreted from tumor 
cells and not from the normal counterpart cells via exosomes (that, as said in the 
Introduction section, are nanovesicles involved in tumor progression), and that Hsp60 is 
present in the membrane of exosomes (in turn becoming a suspicious player in tumor 
progression), we decided to focus our attention for the rest of the study on the 
localization of Hsp60 both in intracellular and extracellular sites in our specimens 
obtained by colon cancer in vivo.  The ELISA assays performed for Hsp60 have shown 
significantly higher levels of this protein in the plasma samples of patients with 
adenocarcinoma of colon compared with healthy controls. This result suggests that the 
Hsp60, in some way, transits from the intracellular to the extracellular environment. 
However, one week after surgical removal of the tumor, Hsp60 levels significantly 
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decreased reaching those of healthy subjects. As a consequence, plasmatic levels of 
Hsp60 seemed to be more useful for monitoring disease progression and for the follow-
up of patients with large bowel carcinoma. Hamelin C et al. has even proposed to 
consider the Hsp60 as a potential serum biomarker for colorectal carcinoma for 
determining prognosis or monitoring therapy (78). An increase in Hsp60 expression as 
compared with normal tissue has been shown for different types of tumor, including 
Hodgkin’s lymphoma, and prostate, ovarian and breast adenocarcinomas (79).  Zhao M 
et al. have furthermore investigated the levels of Hsp27 circulating in patients with 
epithelial ovarian cancer and have showed that the circulating Hsp27 levels were 
increased in epithelial ovarian cancer and correlated with peritoneal metastases. The 
authors have suggested that the evaluation of serum Hsp27 levels may be used as a 
potential additional indicator for peritoneal metastases in epithelial ovarian cancer and 
response to treatment (80). Moreover, the presence of Hsp60 in the circulation 
stimulates the question of why and how this protein passes from the cells into the 
bloodstream of tumor patients. We performed then a set of experiments to study the 
localizzation of Hsp60 in tumor samples, compared to normal tissue, by immunogold at 
TEM. In cancer cells Hsp60 was localized not only in and around the mitochondria as in 
normal cells, but also in the cytosol very close to the plasma membrane and in the 
plasma membrane. These evidences have suggested an active trafficking of this 
chaperon in the regions between the cell cytosol and plasma membrane. This trafficking 
of Hsp60 may be involved in the mechanisms of secretion of the same protein in the 
extracellular space. The presence of Hsp60 on the cellular membrane prompted us to 
research the presence of this protein in exosomes isolated from plasma obtained from 
patients with adenocarcinoma of large bowel, to verify whether these vesicles, which 
originate from the plasma membrane, may be involved in the mechanisms of Hsp60 
secretion in the extracellular space. Hsp60 was found at higher levels in the exosomes 
isolated from plasma of all patients studied before tumor removal and, most 
interestingly, these protein levels decreased after surgery. These results have confirmed 
the data obtained from the ELISA assays for Hsp60 and have suggested that the 
secretion of Hsp60 outside the cells may involve the exosomal vesicles. These 
extracellular vesicles are important for the cell-to-cell communication and, Hsp60 
would be considered a key player in the intercellular cross-talk. Exosomal Hsp60 could 
be a potential colon cancer biomarker, for instance, in assessing disease progression and 
response to treatment (follow-up). In a study of human tumor cells, the authors have 
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shown that the secretion for Hsp60 from tumor cells is not due to cell death or 
destruction, but to an active secretion mechanism (54). The authors have showed also 
that Hsp60 is present in the exosomes released from tumor cell in culture. In another 
study of tumor cells, Hsp60 was found integrated in the exosomes membrane (32) and, 
the authors have suggest that Hsp60 in the exosome membrane may play a role as a 
ligand for a receptor on the cells of the immune system or on other tumor cells. In this 
manner Hsp60 could gain an important role in the cross-talk between the cancer cells or 
between cancer cells and immune cells. Moreover, if Hsp60-bearing exosomes will be 
demonstrated to be able to enter in other tumor cells, we can hypothesise to use these 
nanovesicles as vector for a novel targeted anticancer therapy.  
Finally, to better understand the latest data obtained, we performed double 
immunofluorescence experiments for CD68 and Hsp60 on sections of adenocarcinoma 
tissue and in normal counterpart. We focused on CD68 since this is a common marker 
used to detect macrophages, that it is known have receptors for Hsp60, such as TLR2, 
TLR4 and CD14 (81-84). The results obtained have shown that Hsp60 was present in 
almost all cancer cells and, also, in most of macrophages of the lamina propria that 
expressed the positivity for both CD68 and Hsp60 markers. These data reinforce the 
concept that Hsp60 transported by exosomes may, in some way, is transferred within 
immune cells and, therefore, play a role in the mechanisms of cross-talk between cancer 
cells and the cells of the immune system. Further studies will confirm these data and 
assess the presence of Hsp60 also in other types of immune cells (such as lymphocytes 
or NK cells). Subsequently, the immunofluorescence experiments conducted for the 
antigens CD34 and Hsp60 showed positivity in most of endothelial cells for both 
antigens. CD34 is a common marker used to detect vascular endothelial cells. This 
observation suggests that the Hsp60 is able to cross endothelial cells and to pass into the 
bloodstream. Other experiments will permit to better understand the molecular 
mechanisms of this process as well as to shed light about the putative involvement of 
Hsp60 in tumor neoangiogenesis, as already postulated (45).  
Overall our results suggest that Hsp60 may be considered a novel biomarker for 
assessing colon cancer early diagnosis and, possibly, also in follow-up. Moreover, it 
could become also a target for a novel anti-cancer approach (chaperonotherapy) since its 
participation in the mechanisms of colorectal carcinogenesis. The chaperonotherapy is a 
new strategy of anticancer therapy that is gaining increasing importance for some forms 
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of cancer that may be considered as “chaperonopathies by mistake” in which 
Hsps/chaperones are involved in carcinogenesis (85). Chaperonotherapy consists of the 
utilization of Hsps/chaperones for treating chaperonopathies such as cancer. In the 
“negative chaperonotherapy” a drug is used to block the action of chaperones that favor 
the development of cancer, while, in the “positive chaperonotherapy”, the chaperone is 
used to fight against cancer by enhancing normal cellular defenses or stimulating the 
immune system (50). Current anticancer drug-development strategies involve 
identifying, and blocking, novel molecular targets crucial for tumor progression. Hsp60 
seem to be involved in colorectal carcinogenesis, and for this reason it could become the 
target to be hit in the anticancer therapy. A drug that blocks the action of Hsp60 would 
inhibit the mechanisms by which this chaperone enhances tumor growth or tumor 
progression (84). At the same time, cancer specific Hsp60-bearing exosomes might be 
used as vector for anticancer drugs. However, further studies should be conducted to 
better understand the molecular mechanisms that underlie the involvement of Hsp60 in 
colorectal carcinogenesis and the ways in which this protein may be involved in 
therapeutic strategies. 
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